Page last updated: 2024-12-07
versiconal hemiacetal acetate
Description
Versiconal hemiacetal acetate is a fungal metabolite produced by Aspergillus versicolor, a common mold found in various environments, including indoor spaces. It is a member of the versicolorin family, known for their potent mutagenic and carcinogenic properties. Versiconal hemiacetal acetate exhibits cytotoxic activity against various cell lines and has been linked to adverse health effects, including liver damage and cancer development. Its structure and biological activity have been extensively studied to understand its mechanisms of toxicity and potential therapeutic applications. Researchers investigate its synthesis and metabolism to develop strategies for mitigating its harmful effects. Furthermore, the compound has gained attention for its potential applications in agriculture and biotechnology, where its bioactivity could be harnessed for controlling pests and diseases.'
versiconal hemiacetal acetate: intermediate in biosynthesis of aflatoxin B1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
versiconal hemiacetal acetate : An anthrafuran that is 2,3-dihydroanthra[2,3-b]furan-5,10-dione substituted at positions 2, 4, 6 and 8 by hydroxy groups and at position 3 by a 2-acetoxyethyl group. An intermediate in the biosynthesis of aflatoxin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 107991 |
CHEBI ID | 71637 |
MeSH ID | M0088424 |
Synonyms (9)
Synonym |
62886-00-4 |
versiconal hemiacetal acetate |
3-(2-(acetyloxy)ethyl)-2,3-dihydro-2,4,6,8-tetrahydroxyanthra(2,3-b)furan-5,10-dione |
2-(2,4,6,8-tetrahydroxy-5,10-dioxo-2,3-dihydronaphtho[2,3-f][1]benzofuran-3-yl)ethyl acetate |
anthra(2,3-b)furan-5,10-dione, 3-(2-(acetyloxy)ethyl)-2,3-dihydro-2,4,6,8-tetrahydroxy- |
CHEBI:71637 |
2-(2,4,6,8-tetrahydroxy-5,10-dioxo-2,3,5,10-tetrahydroanthra[2,3-b]furan-3-yl)ethyl acetate |
Q27139775 |
DTXSID00978634 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
Class | Description |
anthrafuran | Any organic heterotetracyclic compound consisting of a furan ring ortho-fused to an anthracene. |
lactol | Cyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues. |
polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
acetate ester | Any carboxylic ester where the carboxylic acid component is acetic acid. |
palmitoyl amino acid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (27.27) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.93 (24.57) | Research Supply Index | 2.48 (2.92) | Research Growth Index | 4.42 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |